Biosimilar Patent Thicketing Has Cost US $7.6bn
A recent study by the AAM’s Biosimilars Council has found that delayed access to biosimilars has cost the US healthcare system $7.6bn since 2015; meanwhile, Medicare has foregone more than $1.2bn in savings from biosimilars since 2015.
You may also be interested in...
The AAM’s senior vice-president, Jeffrey Francer, has offered suggestions to US lawmakers on how to curb anti-competitive tactics used by originators.
The AAM’s Biosimilars Council has said “rebate traps” and other barriers to biosimilar adoption have cost the US healthcare system $2.2bn in lost savings since 2015. That’s on top of patent abuses which the council calculated in a June report have cost the healthcare system $7.6bn – bringing total lost savings from biosimilars to nearly $10bn.
AbbVie’s proposed acquisition of Allergan unites two companies that have gained notoriety for their exhaustive and unconventional efforts, respectively, to extend the patents of key products.